Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769153 · ClinicalTrials.gov registry record · Phase 1
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
A Phase 1 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Alcon Research.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT05769153 is a Phase 1 study of Neovascular Age-related Macular Degeneration (nAMD) that is actively recruiting participants, run by Alcon Research. The registered enrollment target is 140 participants, below the 193-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT05769153, a Phase 1 study of Neovascular Age-related Macular Degeneration (nAMD), is actively recruiting participants, sponsored by Alcon Research.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Conditions Studied
Interventions
- DRUG AR-14034 SR implant lower dose
- DRUG AR-14034 SR implant higher dose
- DRUG AR-14034 SR implant
- DRUG Aflibercept Injection
- DRUG Sham procedure
Study Locations (20)
Florida
- Florida Retina Institute - Jacksonville
- Mid Florida Eye Center - Mt. Dora
- Florida Retina Institute - Orlando
- Retina Specialty Institute - Pensacola
- Eye Associates of Pinellas - Pinellas Park
- Center for Retina and Macular Disease - Winter Haven
California
- The Retina Partners - Encino
- Retina Associates of Orange County - Laguna Hills
- Northern California Retina Vitreous Associates Medical Group - Mountain View
- Eye Research Foundation - Newport Beach
- Azul Vision Pasadena - Pasadena
Arizona
- Associated Retina Consultants - Gilbert - Gilbert
- Associated Retina Consultants - Phoenix - Phoenix
- Retina Associates of SW PC - Tucson
Georgia
- Southeast Retina Center - Augusta
- Thomas Eye Group Main Office - Sandy Springs
Alabama
- Trinity Research Group - Dothan
Colorado
- Retina Consultants of Southern Colorado - Colorado Springs
Connecticut
- Retina Group of New England | Waterford - Waterford
Illinois
- University Retina and Macula Associates, PC - Oak Forest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-12-06 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05769153
The ClinicalTrials.gov registry entry for NCT05769153 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target (27% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 5 interventions - of which AR-14034 SR implant lower dose is the first listed.
NCT05769153 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05769153 about?
NCT05769153 is a clinical study titled "Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)". The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
What is the current status of trial NCT05769153?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2023-12-06. Estimated completion is 2027-10.
What conditions does trial NCT05769153 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).
What interventions are being tested in trial NCT05769153?
The interventions under investigation include: AR-14034 SR implant lower dose (DRUG), AR-14034 SR implant higher dose (DRUG), AR-14034 SR implant (DRUG), Aflibercept Injection (DRUG), Sham procedure (DRUG).
Who is sponsoring clinical trial NCT05769153?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05769153 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration (nAMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
RECRUITING · Phase 3
-
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 3
-
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 3
-
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 4
-
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.